双特异性和三特异性免疫细胞参与剂用于血液性恶性瘤的免疫治疗
Antonio Tapia-Galisteo1,2,3, Luis Álvarez-Vallina4,5,6, Laura Sanz7
1Immuno-Oncology and Immunotherapy Group, Biomedical Research Institute Hospital Universitario, 12 de Octubre, Madrid, Spain.
Journal of hematology & oncology
|July 27, 2023
概括
工程免疫细胞参与者,包括T细胞和NK细胞参与者,正在彻底改变血液恶性瘤治疗. 这些强大的双特异性和三特异性抗体为复发性或耐火性癌症提供了新的希望.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 免疫细胞参与者是设计用于弥合瘤细胞和免疫效应细胞的工程抗体.
- 它们具有向瘤相关抗原和免疫细胞受体的武器,如CD3 (T细胞) 和CD16a (NK细胞).
- 该领域近期经历了加速发展,获得了多次FDA批准,并在临床试验中进行了众多候选试验.
研究的目的:
- 审查免疫细胞参与剂在治疗血液性恶性瘤中的当前情况和未来潜力.
- 突出两种特异性和三种特异性抗体格式的进步.
- 讨论对复发性或耐药性癌症治疗模式的潜在影响.
主要方法:
- 审查最近的FDA批准和正在进行的免疫细胞激活剂临床试验.
- 分析不同抗体格式 (双特异性,三特异性) 及其向策略.
- 疗效和潜在副作用概况的比较.
主要成果:
- 该领域取得了显著的发展势头,在2022-2023年获得了三项批准,以及更多的监管审查.
- 与传统单克隆抗体相比,T细胞参与剂显示出更高的功效.
- 双特异性NK细胞参与剂显示出有希望的疗效与潜在的较轻的副作用.
- 三特异性抗体提供了增强的特异性和效应器功能的调制.
结论:
- 免疫细胞参与者即将彻底改变血液恶性瘤治疗,特别是在复发或耐药病例中.
- 格式和目标的多样性表明治疗领域正在迅速发展.
- 工程抗体代表了癌症免疫治疗中的范式转变.
更多相关视频
06:10Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
Published on: May 9, 2025
336
08:17A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
Published on: August 15, 2019
14.5K
相关概念视频
Tumor Immunotherapy
558
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
558
B Cell Activation and Differentiation
1.8K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.8K
T Cell Activation and Clonal Selection
812
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
812
Special Features of Adaptive Immunity
879
The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
879
